혈관 운동 증상을 동반한 여성 갱년기 우울증 환자에서 Venlafaxine Hydrochloride Extended Release의 치료효과에 대한 개방 관찰 연구

Efficacy of Venlafaxine Hydrochloride Extended Release for the Treatment of Perimenopausal Depressive Women with Vasomotor Symptoms : Open-Label Observation Study

본 연구는 갱년기 한국 여성의 우울 증상과 혈관 운동 증상에 있어 venlafaxine hydrochloride extended release의 치료 효과를 평가하였다. 혈관 운동 증상을 동반한 33명의 여성 갱년기 우울증 환자를 대상으로 37.5 mg/day, 75 mg/day 용량의 venlafaxine hydrochloride extended release를 8주간 투약하였다. HAMD, HAMA, CGI-S와 함께 갱년기 증상 평가 척도인 GCS를 통해 경과를 평가하였다. 본 연구 결과 venla-faxine hydrochloride는 8주 동안 HAMD 및 CGI, GCS를 포함한 전체 척도 점수에 있어 유의한 호전을 보였다. 33명의 대상자 중 1명이 심한 오심으로 중도 탈락했다. 이는 일반 갱년기 한국 여성의 우울 증상과 혈관 운동 증상의 치료에 있어 venlafaxine hydrochloride가 효과적인 치료안이 될 수 있다는 가능성을 보여준다. 본 연구 결과는 대조군 없이 진행된 개방 관찰 연구로 결과의 입증을 위한 장기간의 이중맹검 연구가 필요할 것이다.

Objective During the transition to menopause, various symptoms including vasomotor symptoms and depressed mood lead to low quality of life. We investigated the effect of low-dose venlafaxine hydrochloride extended release on depressed mood and vasomotor symptoms of perimenopausal women. Methods 33 perimenopausal women fulfilling Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for a depressive episode were enrolled between January 2014 and May 2014. Subjects were prescribed 37.5 mg/day or 75 mg/day venlafaxine hydrochloride according to clinician’s judgement, and the dosages were maintained for 8 weeks. Depressed mood and other psychological difficulties were evaluated by using Hamilton Rating Scale for Depression (HAMD), Hamilton Rating Scale for Anxiety (HAMA), Clinical Global Impression-Severity. Climacteric symptoms including vasomotor symptoms were evaluated by using Greene Climacteric Scale (GCS). For statistical analysis, paired t-test was used. Results Significant decreases in HAMD, HAMA, GCS scores were observed after 2 weeks of treatment and the trends continued until the end of the study. The scores of HAMD significantly decreased, 28 of them reached remission (HAMD ≤7). The scores on vasomotor symptoms of GCS after 8 week treatment significantly decreased compared to baseline (13.1±5.0, p<0.01). Conclusion These results suggest that venlafaxine hydrochloride is effective and tolerable treatment option for vasomotor symptoms and depressed mood in perimenopausal women. To validate our results, furthur studies with double-blind, placebo controlled will be needed.